When is a further clinical trial justified?

BMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e5913 (Published 13 September 2012)
Cite this as: BMJ 2012;345:e5913

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Manuela L Ferreira, research fellow1,
  2. Robert D Herbert, professor2,
  3. Michael J Crowther, research associate3,
  4. Arianne Verhagen, associate professor4,
  5. Alex J Sutton, professor of medical statistics3
  1. 1The George Institute for Global Health, University of Sydney, PO Box M201, Missenden Road, NSW 2050, Australia
  2. 2Neuroscience Research Australia, Sydney, Australia
  3. 3Department of Health Sciences, University of Leicester, UK
  4. 4Department of General Practice, Erasmus Medical Centre University, Rotterdam, Netherlands
  1. Correspondence to: M L Ferreira mferreira{at}georgeinstitute.org.au
  • Accepted 21 August 2012

High quality randomised trials provide unbiased estimates of the effects of health interventions, but the findings of a single trial are rarely conclusive. Usually data from several similar trials must be pooled together to draw firm conclusions about the effectiveness of an intervention. This article considers how to determine whether data from existing trials are conclusive and, if not, whether a further trial is justified.

Even on their own the best randomised trials do not usually provide convincing evidence of the effectiveness (or lack of effectiveness) of an intervention. Consensus about effectiveness is usually only achieved when a meta-analysis of several high quality trials shows a statistically significant effect. Until such a consensus is achieved researchers may claim that a new trial is justified. We will refer to this as the “conventional approach” to justification of a new trial.

Two problems, and solutions

There are two problems with the conventional approach. The first concerns the interpretation of existing evidence: interpretation of data from clinical trials or meta-analyses is reduced to a decision about whether the intervention is “effective” or “ineffective.”1 The simplistic classification of interventions as effective or ineffective fails to make the important distinction between interventions that have trivial effects and those that have worthwhile effects.

A health intervention produces “worthwhile” effects when it does more good than harm. Here we must use the term “harm” to include all of the negative aspects of interventions: from a patient’s perspective, these could include risks of adverse events, pain or discomfort, cost, or inconvenience. The role of clinical trials is to provide unbiased estimates of the beneficial effects of health interventions so that it can be ascertained whether those effects outweigh risks, costs, and inconvenience.

Several methods have been developed to determine what beneficial effect would outweigh the risks, costs, and inconvenience of an …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL